There is on-going development of generic EU CTD Dossier of Repaglinide, tablets, 0.5/1/2 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.
More details at: http://www.rxlist.com/prandin-drug.htm.Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Monitoring Downloads Section
You can easily monitor all new articles and reports published at Downloads Section of Farmavita.Net. Click on the RSS button and bookmark this RSS feed. RSS button is located beside title “Farmavita.Net - Pharmaceutical Licensing Network :: File Repository“.